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AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE
Association of Severe Intrahepatic Cholestasis of
Pregnancy With Adverse Pregnancy Outcomes: A
Prospective Population-Based Case-Control Study
Victoria Geenes,1 Lucy C. Chappell,2 Paul T. Seed,2 Philip J. Steer,3
Marian Knight,4 and Catherine Williamson1,2
Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disease, charac-
terized by maternal pruritus and raised serum bile acids. Our objectives were to describe
the epidemiology and pregnancy complications associated with severe ICP and to test
the hypothesis that adverse perinatal outcomes are increased in these women. A prospec-
tive population-based case-control study with national coverage was undertaken using
the UK Obstetric Surveillance System (UKOSS). Control data for comparison were
obtained from women with healthy pregnancy outcome through UKOSS (n 5 2,232),
St Mary’s Maternity Information System (n 5 554,319), and Office for National Statis-
tics (n 5 668,195). The main outcome measures investigated were preterm delivery,
stillbirth, and neonatal unit admission. In all, 713 confirmed cases of severe ICP were
identified, giving an estimated incidence of 9.2 per 10,000 maternities. Women with
severe ICP and a singleton pregnancy (n 5 669) had increased risks of preterm delivery
(164/664; 25% versus 144/2200; 6.5%; adjusted odds ratio [OR] 5.39, 95% confidence
interval [CI] 4.17 to 6.98), neonatal unit admission (80/654; 12% versus 123/2192;
5.6%; adjusted OR 2.68, 95% CI 1.97 to 3.65), and stillbirth (10/664; 1.5% versus 11/
2205; 0.5%; adjusted OR 2.58, 95% CI 1.03 to 6.49) compared to controls. Seven of
10 stillbirths in ICP cases were associated with coexisting pregnancy complications.
These differences remained significant against national data. Risks of preterm delivery,
meconium-stained amniotic fluid, and stillbirth rose with increasing maternal serum
bile acid concentrations. Conclusion: In the largest prospective cohort study in severe
ICP to date, we demonstrate significant increased risks of adverse perinatal outcomes,
including stillbirth. Our findings support the case for close antenatal monitoring of
pregnancies affected by severe ICP. (HEPATOLOGY 2014;59:1482-1491)
See Editorial on Page 1220
I
ntrahepatic cholestasis of pregnancy (ICP) is a
pregnancy-specific liver disease, characterized by
maternal pruritus and raised serum bile acids. It
typically presents in the third trimester with rapid resolu-
tion of symptoms and biochemical abnormalities postpar-
tum. Previous retrospective case series have suggested that
ICP is associated with an increased risk of adverse fetal out-
comes, including spontaneous preterm labor, meconium
staining of the amniotic fluid, low Apgar scores, and sud-
den intrauterine death, but there have been concerns over
publication bias and case ascertainment when considering
the risk against that of the general pregnant population.1,2
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There are accumulating data indicating that the risk
of fetal complications relates to high levels of circulating
bile acids.3-10 One prospective cohort study from Swe-
den examined the relationship between adverse fetal out-
comes and maternal serum bile acid levels; there was a
1%-2% increased risk of spontaneous preterm delivery,
asphyxial events, and meconium-stained amniotic fluid
with every 1 lmol/L increase in maternal serum bile
acids, but this was not statistically significant until the
fasting maternal serum bile acid level exceeded 40
lmol/L. However, only 96 women (19%) had bile acids
exceeding this level.3 Although these findings have been
partially replicated in other populations,6-8,10 no studies
have been large enough to evaluate the relationship
between maternal serum bile acids and stillbirth. Fur-
thermore, there have been no prospective studies exam-
ining the relationship between maternal nonfasting
serum bile acid levels and perinatal outcomes.
We hypothesized that the risks of adverse perinatal
outcomes, including stillbirth, are increased in women
with nonfasting serum bile acid levels 40 lmol/L, and
that the extent of the rise in bile acid level can be used
to predict the likelihood of specific adverse outcomes.
Materials and Methods
A prospective population-based cohort study was carried
out over 12 months (June 2010 to May 2011). Cases of
severe ICP were identified through the UK Obstetric Sur-
veillance System (UKOSS). UKOSS is a national system
that allows collection of information about specific uncom-
mon disorders of pregnancy (i.e., conditions that affect no
more than 1 in 2,000 births) from all hospitals with
consultant-led maternity units in the UK; 209 of 213 eligi-
ble units reported cases for this study. Severe ICP was
defined as serum bile acid levels 40 lmol/L at any time
during pregnancy. Exclusion criteria included women with
pruritus but no elevation in serum bile acids, and pregnan-
cies ending before 24 weeks’ gestation. Biochemical, man-
agement and outcome data were collected (www.npeu.
ox.ac.uk/ukoss/dcf). Data were anonymized and double-
entered into a customized database. The overall incidence
with 95% confidence intervals (CIs) of severe ICP was cal-
culated using the most recently available national birth
data11-13 as a denominator for the number of maternities
during the study period (n5 798,634), less the number of
maternities at the four nonparticipating units (n 5
21,922). Control data were obtained from three sources. A
cohort of women with uncomplicated singleton (n 5
2,205) or twin (n 5 27) pregnancies identified from the
UKOSS database of control women from other studies
was used for the majority of the comparisons (https://
www.npeu.ox.ac.uk/ukoss/completed-surveillance). All
cases meeting the definition are reported to the central
data collection unit by a clinician without requiring deter-
mination of past exposure, while controls were taken from
the UKOSS database, in order to minimize information
bias. Outcomes were restricted to those that could be
reported without subjective interpretation to minimize
interviewer bias. Response bias should also be minimized
by the use of a national survey tool (UKOSS), with 98%
of maternity units contributing data. As the UKOSS con-
trol database does not have information about meconium-
stained amniotic fluid, the St Mary’s Maternity Informa-
tion System (SMMIS) was used; routine maternity data
were collected prospectively from all pregnancies
(585,291) booked at 15 maternity units in North West
London, from 1988 to 2000.14,15 National data were
obtained from the Office of National Statistics, England,
for 2010-2011 (n5 668,195).16 Ethnicity was categorized
into groups as defined by the Office for National Statistics
(UK).
The perinatal outcomes studied were gestational age
at delivery, iatrogenic and spontaneous preterm deliv-
ery, stillbirth, mode of delivery, birthweight and birth-
weight centile, 5-minute Apgar score 7, neonatal
unit admission, and meconium-stained amniotic fluid.
Data on maternal demographics, obstetric, and medi-
cal history were collected for all women; data on
serum biochemistry, management, and monitoring
were collected for the ICP cases. Data missing due to
incomplete reporting are indicated in the footnotes of
the relevant tables.
The study number of 700 cases was prespecified in
the protocol as being of sufficient size to enable esti-
mation of uncommon adverse perinatal outcomes
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(with intrauterine death estimated at 0.5% to 3%).
Statistical analysis was performed using Stata v. 11.2
(StataCorp, College Station, TX). Unadjusted and
adjusted odds ratios or mean differences and 95% CIs
were calculated. Perinatal outcome data were adjusted
for maternal age, body mass index (BMI), occupation,
ethnicity, and parity. Data were available on >99% of
cases for all demographic variables except BMI
(91.7%) and occupational group (83%). As BMI was
missing in 247 (24 cases and 223 controls) of 2,963
women, multiple imputation (50 repeats) and proxy
indicator analysis were used to estimate the association
between ICP and perinatal outcomes, based on birth-
weight, delivery mode, ethnic group, and parity. Only
data from the multiple imputation model are pre-
sented here, as the results from both methods were
very similar. No imputation was used for occupational
group. The numbers of values for biochemical tests are
provided. Logistic regression (LR) was used to establish
a relationship between adverse perinatal outcomes and
maternal biochemical parameters (peak level of serum
bile acids, alanine transaminase [ALT], aspartate
transaminase [AST], bilirubin, and gamma glutamyl
transferase [GGT]). Correlations between different
maternal biochemical parameters were examined using
Spearman’s correlation.
Results
Incidence and Maternal Characteristics. During
the study period there were 713 confirmed cases of
severe ICP (Fig. 1) in an estimated 776,712 deliveries,
giving an estimated incidence of 9.2 per 10,000 mater-
nities (95% CI 8.5-9.9 per 10,000).
For singleton pregnancies, the mean gestation was
32 6 4 weeks (SD 5.3 days) for onset of symptoms
and 33 6 4 weeks (SD 5.2 days) for diagnosis. Three
percent (23 cases) were diagnosed before 20 weeks’
gestation. The mean gestation for both onset of symp-
toms and diagnosis were earlier in twin pregnancies
(31 6 0 and 31 6 6, weeks respectively; SD 4.7 and
6.1 days).
The demographic and obstetric characteristics of
women with severe ICP are shown in Table 1. Women
with ICP were more likely to be Asian (OR 1.93,
95% CI 1.50 to 2.49) and there were more twin preg-
nancies (6.2%, 44 women) than the control popula-
tion (1.2%, 27 women). Given that the rates of the
perinatal outcomes of interest were likely to be higher
in twin pregnancies, we included only data from
singleton pregnancies in all subsequent analyses (ICP
n 5 669, control n 5 2,205). Data comparing
demographic and clinical characteristics of ICP twin,
ICP singleton, and control twin pregnancies are given
in Supporting Tables 1 and 2 and Supporting Fig. 1.
Of the remaining 669 singleton pregnancies, 4.9%
(33 women) had a history of gallstones and 1.2% (8
women) had known coexistent hepatitis B infection.
There was one woman with documented hepatitis C
infection and one woman reported hepatic impairment
following use of the oral contraceptive pill. Of the 349
multiparous women, 42% (145 women) had a history
of ICP and 9.7% (34 women) had previous pree-
clampsia or HELLP (hemolysis, elevated liver enzymes,
low platelets) syndrome.
The maternal serum biochemistry from ICP cases is
shown in Table 2 and Supporting Table 3. There were
no significant correlations between markers of liver
function (ALT, AST, bilirubin, and GGT) and mater-
nal serum bile acids (data not shown).
Management of Severe ICP. Ursodeoxycholic acid
treatment was given to 72% (481 women) of the cases
(Table 3); the starting doses used ranged from 150 mg
to 2 g per day. The second most common drug used
was vitamin K, given to 55% (368 women) of cases.
Rifampicin was used in seven cases for symptoms or
worsening biochemical markers despite treatment with
UDCA. Further details of antenatal fetal monitoring,
pharmacological and nonpharmacological management
of ICP are shown in Table 3.
Pregnancy Outcomes in Severe ICP. Women with
severe ICP delivered earlier than controls (mean differ-
ence in gestational age 22.12 weeks; 95% CI 21.98
Fig. 1. Flow diagram showing the case ascertainment and com-
pleteness of reporting.
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to 22.27) (Table 4). There was a significant increase
in the number of spontaneous and iatrogenic preterm
deliveries. The majority of preterm deliveries were
iatrogenic, with 17% (114 women) in the ICP popula-
tion compared to 2.7% (60 women) in the controls
(unadjusted OR 7.39; 95% CI 5.33 to 10.25) being
Table 1. Sociodemographic and Obstetric Histories of Women With Severe ICP
and Healthy Controls With Singleton Pregnancies
ICP Population n (%) UKOSS Controls n (%) Comparison*
Total 669† 2,205‡
Sociodemographic features
Maternal age (mean 1 SD) 29.6 (6.3) 29.0 (6.1) MD 0.55 (0.0 to 1.09)
Ethnicity
White 524 (78%) 1771 (80%) —
Black 14 (2.1%) 130 (5.9%) OR 0.36 (0.21 to 0.64)
Asian 111 (17%) 194 (8.8%) OR 1.93 (1.50 to 2.49)
Other 20 (3.0%) 110 (5.0%) OR 0.61 (0.38 to 1.00)
Body mass index (mean 1 SD) 25.1 (4.9) 25.7 (5.5) MD 20.54 (20.09 to 20.99)
< 18.5 15 (2.2%) 56 (2.5%) OR 0.80 (0.45 to 1.43)
18.5 - 25 353 (52.7%) 1050 (47.6%) —
25 - 30 184 (27.5%) 537 (24.4%) OR 1.02 (0.83 to 1.25)
30 - 35 63 (9.4%) 227 (10.3%) OR 0.83 (0.61 to 1.12)
> 35 30 (4.5%) 139 (6.3%) OR 0.64 (0.42 to 0.97)
Occupation
Managerial 173 (25.9%) 556 (25.2%) OR 1.26 (0.97 to 1.65)
Intermediate 140 (20.9%) 468 (21.2%) OR 1.21 (0.92 to 1.60)
Manual and unskilled 202 (30.2%) 591 (26.8%) OR 1.39 (1.07 to 1.79)
Unemployed 32 (4.8%) 113 (5.1%) OR 1.15 (0.74 to 1.79)
Student 7 (1.0%) 11 (0.5%) OR 2.58 (0.98 to 6.80)
Obstetric history
Parity
0 317 (47.3%) 968 (43.9%) —
1 201 (30%) 716 (32.5%) OR 0.86 (0.70 to 1.05)
>2 148 (22%) 517 (23.4%) OR 0.87 (0.70 to 1.09)
Twin pregnancy 44 (6.2%) 27 (1.2%)
Current pregnancy complications
Preeclampsia 44 (6.6%) n/a N/a
Gestational diabetes 41 (6.1%) n/a N/a
*OR: odds ratios and 95% confidence intervals; MD: mean difference and standard deviation.
— 5 the reference group to which the comparisons are made.
n/a 5 data not available for comparison.
†Variable denominator numbers were a consequence of incomplete reporting and were as follows: BMI n 5 645, parity n 5 666 and occupational group n 5 664.
‡Variable denominator numbers were a consequence of incomplete reporting and were as follows: BMI n 5 2,009, parity n 5 2,201, and occupational group
n 5 2,009.
Table 2. Maternal Serum Biochemistry; All Results Are Given as Median (IQR)
Level at time of
diagnosis
Gestation
(weeks1days)
at measurement Peak level
Gestation
(weeks1days) at
measurement
Level at time
of delivery
Gestation
(weeks1days)
at measurement
Typical reference
range for pregnancy*
Serum bile acids (lmol/L) 47
(27 to 75)
3414
(3114 to 3614)
72.5
(53 to 109)
3516
(3410 to 3711)
46
(21 to 75)
3711
(3612 to 3810)
< 14 lmol/L
Alanine transaminase
(IU/L)
92
(41 to 202)
3414
(3114 to 3614)
151
(63 to 281)
3514
(3313 to 3712)
80
(29 to 180)
3712
(3612 to 3810)
6 - 32
Aspartate transaminase
(IU/L)
82.5
(44 to 180)
3414
(3114 to 3614)
110
(59 to 226)
3515
(3315 to 3712)
79
(37 to 174)
3712
(3612 to 3810)
11 - 30
Bilirubin (lmol/L) 10
(7 to 14)
3414
(3114 to 3614)
12
(8 to 17)
3515
(3313 to 3712)
9
(7 to 14)
3712
(3612 to 3810)
3- 14
Gamma glutamyl
transferase
(IU/L)
26
(16 to 41)
3414
(3114 to 3614)
28
(18 to 46)
3511
(3310 to 3710)
22
(12 to 40)
3711
(3612 to 3716)
3 - 41
*Please note that some hospitals use different reference ranges and it is recommended that the upper limit of normal for liver transaminases, bilirubin and
gamma glutamyl transferase is reduced by 20% in pregnancy.
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induced or delivered electively (Fig. 2; Supporting
Table 4). The differences in rates of preterm delivery
remained significant following correction of the data
for potential confounding factors (maternal age, BMI,
occupation, ethnicity, and parity).
In our unadjusted analysis, there were significantly
higher rates of stillbirth in the ICP population (1.5%,
10/664 versus 0.5%, 11/2,205) (OR 3.05; 95% CI
1.29 to 7.21) (Table 4). There was also an increased
risk of admission to the neonatal unit (OR 2.34; 95%
CI 1.74 to 3.15). These differences remained signifi-
cant following adjustment for potential confounding
factors, and when compared to national data. The
main reasons given for admission to the neonatal unit
were preterm delivery (45%, 36 babies) and respiratory
problems (30%, 24 babies). There were no cases of
meconium aspiration syndrome. The median duration
of stay on the neonatal unit was 7 days (IQR 2.25 to
13.75). Meconium-stained amniotic fluid was observed
in 16% (106 women) of ICP cases, and occurred at
lower gestational weeks than in the control population
(Fig. 3). The odds ratio for meconium staining of the
amniotic fluid in women with severe ICP compared to
Table 3. Pharmacological and Antenatal Management of
Severe ICP
Drug Therapy n (%)
Ursodeoxycholic acid 481 (72%)
Ursodeoxycholic acid and rifampicin 7 (1%)
Vitamin K 368 (55%)
Cholestryamine 3 (0.5%)
S-adenosyl methionine 0 (0)
Guar gum 0 (0)
Dexamethasone / betamethasone 33 (4.9%)
Antihistamines 271 (41%)
Antenatal fetal monitoring
Cardiotocography 581 (87%)
Fetal movement charts 29 (4.3%)
Ultrasound scan for fetal growth 437 (65%)
Doppler ultrasound scan 315 (47%)
Imaging
Liver ultrasound scan 288 (43%)
Table 4. Maternal and Perinatal Outcomes of Severe ICP and Healthy Pregnancies
ICP n (%)
UKOSS
Controls n (%)
National ONS
Controls n (%)
N 5 669y N 5 2,205z
Unadjusted
Comparison* P Value
Adjusted
Comparison* P Value N 5 668,195
Unadjusted
Comparison* P Value
Mean (SD) gestational age
at delivery (weeks)
37.5
(1.6)
39.6
(1.9)
MD 22.12
(21.98 to 22.27)
<0.001 MD 22.21
(22.05 to 22.37)
<0.001 n/a n/a n/a
Preterm delivery 164
(25%)
144
(6.5%)
OR 4.68
(3.67 to 5.98)
<0.001 OR 5.39
(4.17 to 6.98)
<0.001 47657
(8.9%)
OR 3.39
(2.84 to 4.04)
<0.001
Spontaneous < 37 weeks 50
(7.5%)
84
(3.8%)
OR 2.05
(1.43 to 2.94)
<0.001 OR 2.25
(1.54 to 3.27)
<0.001 28444
(5.3%)
OR 1.46
(1.10 to 1.95)
0.009
Iatrogenic < 37 weeks 114
(17%)
60
(2.7%)
OR 7.39
(5.33 to 10.25)
<0.001 OR 8.75
(6.19 to 12.37)
<0.001 19213
(3.6%)
OR 5.38
(4.40 to 6.58)
<0.001
Mode of delivery
Cesarean section 164
(25%)
508
(23%)
OR 1.09
(0.89 to 1.34)
0.39 n/a n/a 162512
(24.3%)
1.09
(0.93 to 1.29)
0.29
Birthweight (g) 3049.5 3357.5 MD 2308
(2262 to 2353)
<0.001 MD 2309
(2263 to 2355)
<0.001 n/a n/a n/a
Mean (SD) customized
birthweight centile
47.6
(28.8)
40.8
(28.3)
MD 6.7
(4.0 to 9.5)
<0.001 MD 6.2
(3.4 to 8.9)
<0.001 n/a n/a n/a
> 90th Centile 54
(8.5%)
82
(7.0%)
RR 1.21
(0.87 to 1.68)
0.26 RR 1.14
(0.82 to 1.59)
0.44 n/a n/a n/a
< 10th Centile 70
(11%)
193
(16%)
RR 0.67
(0.52 to 0.86)
0.002 RR 0.70
(0.54 to 0.91)
0.007 n/a n/a n/a
Adverse outcomes
Stillbirth 10
(1.5%)
11
(0.5%)
OR 3.05
(1.29 to 7.21)
0.011 OR 2.58
(1.03 to 6.49)
0.044 2626
(0.44%)
OR 3.05
(1.65 to 5.63)
<0.001
5 min Apgar  7 18
(2.8%)
14
(1.6%)
OR 1.81
(0.89 to 3.66)
0.101 OR 1.92
(0.92 to 3.99)
0.081 n/a n/a n/a
Neonatal unit admission 80
(12%)
123
(5.6%)
OR 2.34
(1.74 to 3.15)
<0.001 OR 2.68
(1.97 to 3.65)
<0.001 n/a n/a n/a
*OR: odds ratios and 95% confidence intervals; MD: mean difference and standard deviation. Adjusted risk ratios are calculated with correction for potential
confounding factors (maternal age, ethnicity, parity, body mass index and occupation).
n/a 5 data not available.
†Variable denominator numbers were a consequence of incomplete reporting and were as follows: preterm delivery and stillbirth n 5 664, caesarean section
n 5 665, Apgar score n 5 643, neonatal unit admission n 5 654.
‡Variable denominator numbers were a consequence of incomplete reporting and were as follows: preterm delivery n 5 2190, caesarean section n 5 2183,
stillbirth n 5 2,187, Apgar score n 5 892, neonatal unit admission n 5 2,185.
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published controls14 was significantly greater at each
week of gestational age up to and including 38 weeks’
gestation. Of those who had a cord blood sample
taken, cord artery pH  7.1 was present in 8.5% (24/
283) and pH  7.0 in 3.5% (10/283). For the pur-
poses of this study a reassuring cord artery pH was
considered to be >7.1, as decreasing cord arterial pH
levels below 7.1 and particularly below 7.0 are associ-
ated with worsening perinatal and long-term infant
outcomes.17 Cardiotocography abnormalities were
recorded in 28% (163 cases). The most common
abnormalities reported were variable decelerations/prel-
abor decelerations (80 cases, 49.1%), early decelera-
tions (14 cases, 10.3%), bradycardia (<110 beats per
minute; 14 cases, 8.6%), and tachycardia (>160 beats
per minute; 11 cases, 6.7%) (Supporting Table 5).
Relationship Between Bile Acids and Fetal Com-
plications. Significant relationships were found
between the maternal serum bile acid level and pre-
term delivery, spontaneous preterm delivery, stillbirth,
and meconium-stained amniotic fluid (Fig. 4; Support-
ing Fig. 2). Logistic regression analysis demonstrated
that a doubling in the level of serum bile acids
increased the risk of all preterm delivery by 68%,
spontaneous preterm delivery by 66%, meconium
staining of the amniotic fluid by 55%, and stillbirth
by 200%. A weaker but still significant relationship
was also found between serum ALT and preterm deliv-
ery, but not with any other adverse outcomes (Sup-
porting Figs. 3, 4). None of the other biochemical
parameters had a significant relationship with any peri-
natal complications.
Characteristics of Stillbirth Cases. There were 10
stillbirths in the ICP population and 11 in the control
population, giving an incidence of 1.5% and 0.5%,
respectively. The median gestational age at delivery in the
ICP stillbirth cases was 36 6 2 (IQR 35 6 4 to 38 6 1
days), compared with 30 6 5 (IQR 28 6 4 to 38 6 0
days) in the controls with a stillbirth. Six of the 10 ICP
stillbirths occurred before 37 weeks’ gestation. Of the
women with stillbirth, 50% of those with ICP were
white, whereas the predominant ethnic group affected in
the control population with stillbirths was Asian (55%).
Seven of 10 ICP cases had coexistent pregnancy compli-
cations, including two cases with preeclampsia, three
with gestational diabetes, and two with nonspecified
complications. Spontaneous preterm delivery was
observed in three ICP stillbirth cases and one control.
There were no small for gestational age babies in the ICP
stillbirth cases, but there were three large for gestational
age babies; none of these mothers had coexistent gesta-
tional diabetes diagnosed prior or subsequent to the loss.
Peak bile acid levels were significantly higher in the still-
birth cases (median 137 lmol/L; IQR 104 to 159) than
in the live births from the ICP cases (median 72 lmol/L;
IQR 53 to 107; P 5 0.0021). There was one neonatal
death among the women with ICP, after term delivery
with meconium-stained amniotic fluid and normal
birthweight.
Discussion
This is the largest prospective study of perinatal out-
comes in women with severe ICP, demonstrating its
association with significantly increased risks of sponta-
neous and iatrogenic preterm delivery, neonatal unit
admission, and stillbirth. The incidence of severe ICP
was 1 case per 1,000 deliveries. The overall incidence
Fig. 3. The incidence of meconium staining of the amniotic fluid by
gestational age in 669 women with severe ICP compared with
514,635 controls with a gestational age from 24 to 44 weeks gesta-
tion. Gestation was calculated as described.14
Fig. 2. Timing of spontaneous and iatrogenic deliveries of singleton
pregnancies in women with severe ICP and controls. TD, term delivery
(37 weeks gestation); PTD, preterm delivery (<37 weeks gestation).
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of ICP in the UK has been estimated at 0.7%,1,18 and
severe ICP accounts for 15% of all ICP in the UK.
Significant positive correlations between maternal
serum bile acid levels and adverse fetal outcomes,
including preterm delivery, spontaneous preterm deliv-
ery, meconium staining of the amniotic fluid, and still-
birth were demonstrated. ALT also has a significant,
albeit weaker, positive correlation with preterm deliv-
ery. A relatively large proportion (17%) of women
with severe ICP were delivered prior to 37 weeks’ ges-
tation. This may reflect concerns with regard to the
risk of fetal death or adverse outcome in pregnancies
complicated by high maternal serum bile acids, and
therefore the clinicians managing these pregnancies
may have preferred a management strategy of induc-
tion of labor prior to 37 weeks despite emerging con-
cerns about special education needs19 and poorer
school performance20 in babies born late preterm. This
is the first study of severe ICP to show a significant
association with stillbirth. It should be noted that a
large proportion (7 of 10) of the women with stillbirth
also had other pregnancy complications. Importantly,
this may indicate that women with severe ICP and
other coexisting conditions require closer monitoring
than those with ICP alone, as the etiology of fetal
death in these cases may be multifactorial.
Use of the UKOSS national data collection system
adds considerable weight to the findings, given the
extensive coverage of UK maternity units by this sur-
veillance method (https://www.npeu.ox.ac.uk/ukoss/
annual-reports), which has been informative previously
for similar cohort studies.21,22 This also enabled
recruitment of a prospective cohort of ICP cases with
serum bile acids 40 lmol/L that is more than seven
times larger than the number of severe ICP cases in
the only previous cohort3 that aimed to establish the
relationship between maternal serum bile acid levels
and adverse pregnancy outcome. Furthermore, the
wide coverage of maternity units provided by UKOSS
obviates the publication bias associated with previous
case series in which selected ascertainment and report-
ing has led to uncertainty over the estimation of
adverse perinatal outcomes. It is therefore likely that
these findings are generalizable to maternity units in
the UK, and to other similar populations.
A further strength of our study is examination of
the relationship between nonfasting maternal serum
bile acid levels and perinatal complications, demon-
strating that the previously described association
observed with fasting bile acid levels3 remains when
postprandial samples are used. As most women are not
fasting when they attend for antenatal care, this means
Fig. 4. The estimated probability and 95% CIs of preterm delivery (A), spontaneous preterm delivery (B), stillbirth (C), and meconium-stained
amniotic fluid (D) in relation to the maternal serum bile acid level, based on simple logistic regression.
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that the results presented here are directly applicable
to all UK maternity units and to other populations in
which nonfasted serum bile acid levels are used for
monitoring ICP. A limitation is the lack of directly
comparable control data for some secondary outcomes,
such as meconium-stained amniotic fluid. Although it
is likely that this would not change the conclusions of
the study, future research should aim to capture com-
plete data on cases and controls.
A limitation of using the UKOSS system to acquire
the data for this study was the inability to obtain pro-
spective data from ICP pregnancies with bile acid lev-
els of 10-39 lmol/L. The criteria for inclusion of a
study in the UKOSS program state that the condition
is an uncommon disorder of pregnancy affecting no
more than 1 in 2,000 births per year in the UK
(https://www.npeu.ox.ac.uk/ukoss/survey-applications).
When we initiated the study we anticipated that ICP
affected 1 in 2,000 pregnant women in the UK.
Therefore, we were unable to use this system to study
ICP with lower bile acid levels as the incidence in the
UK is 0.7%.18 However, the published literature
regarding perinatal outcomes in women with ICP and
lower levels of bile acids are generally reassuring,3 but
further studies are required to fully establish the risk
in this subpopulation.
Our findings of increased risks of adverse perinatal
outcomes in ICP are consistent with previous smaller
studies that reported preterm delivery, fetal asphyxia,
and meconium staining in white-European and Latina
populations.4-8,23 Previous work has led to uncertainty
over the risks of stillbirth; early studies suggested an
increased risk but were considered subject to case
ascertainment bias, while later reports suggested lower
rates of stillbirth, largely attributed to policies of active
management, with increased antenatal fetal monitoring
and elective delivery at around 37 weeks’ gestation.
Interestingly, the most recent study of fetal outcomes
in ICP showed no significant increase in the number
of stillbirths in an actively managed ICP population
compared to controls during the study period (1997-
2009).24 However, this epidemiological study based on
registry data, in common with many others, was not
able to consider the extent of the rise in serum bile
acids when evaluating the stillbirth risk in ICP. Fur-
thermore, the data presented here demonstrate that
despite high rates of iatrogenic preterm delivery
(17%), suggesting the use of policies of active manage-
ment, severe ICP remains associated with a signifi-
cantly increased risk of stillbirth in the UK.
The mechanisms underlying the fetal complications
in ICP are unclear, but appear to relate to the effect of
high levels of bile acids in the fetal compartment.
Spontaneous preterm labor may be explained by a
dose-dependent bile acid effect on myometrial contrac-
tility, as has been demonstrated in rodents.25 Further-
more, myometrial cells from women with ICP are
more responsive to oxytocin, and cells from normal
women demonstrate an increased response to oxytocin
in the presence of bile acids.26,27 Meconium-stained
amniotic fluid may be explained by an increase in
colonic motility secondary to bile acids; 100% of preg-
nant sheep infused with cholic acid have meconium-
stained amniotic fluid but no other signs of fetal dis-
tress.28 Evidence for the involvement of bile acids in
the etiology of neonatal respiratory distress comes
from studies of rabbits undergoing intratracheal injec-
tion of bile acids,29 which results in atelectasis, eosino-
philic infiltration, and the formation of hyaline
membrane, all of which can be reversed by the admin-
istration of surfactant. Interestingly, a recent series of
infants with unexpected respiratory distress in associa-
tion with ICP reported an improvement in condition
following treatment with intratracheal surfactant ther-
apy.30 The mechanisms causing stillbirth in ICP are
poorly understood. At autopsy the babies have no
signs of chronic uteroplacental insufficiency, but do
have evidence of acute anoxia.31 Histological changes
described in the placentas of women with ICP support
the hypothesis of a sudden acute event leading to fetal
death.32 A possible mechanism would be fetal cardiac
arrhythmia and there are case reports of this in the lit-
erature.33 Further evidence for this hypothesis comes
from studies of cultured rat neonatal cardiomyocytes,
which have a decreased rate of contraction when
exposed to bile acids and also develop arrhythmogenic
activity.34,35
The implications of this study are that women with
severe ICP warrant increased surveillance for adverse
perinatal outcomes. Clinicians need to make a difficult
and individualized judgment as to whether the risks of
early delivery are greater than the risks associated with
the disease. A previous feasibility trial compared early
delivery against expectant management in women with
ICP,18 but the study did not have sufficient power to
provide a definitive answer on best management. The
finding that the infants of women with severe ICP had
normal birthweight centiles and were not growth
restricted suggests that management strategies involving
ultrasound assessment of fetal growth for identification
of placental dysfunction will not be of use in identify-
ing babies at risk. However, the risk of adverse perina-
tal outcome is associated with increased serum bile
acids, suggesting that bile acids should be routinely
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used for surveillance, contrary to the most recent
national guidelines on management of the disease.2 Our
finding of increased stillbirth in women with ICP and
serum bile acids 40 lmol/L provides the first evidence
base on which to offer delivery from 37 weeks’ gesta-
tion, as the benefits of intervention are likely to out-
weigh the risks of preterm delivery for the fetus.
Future research now needs to focus on improving
prediction and treatment of severe ICP. Women with
genetic variants in biliary transporters36,37 and recep-
tors38 have increased susceptibility to ICP. New bio-
markers may also be useful in identifying women with
ICP at greatest risk of subsequent adverse outcomes.
Specific compounds of interest are sulfated progester-
one metabolites.39-41 Ursodeoxycholic acid has been
shown to improve pruritus in women with ICP9,18,40
but definitive proof of its protective effect on the fetus
remains elusive until larger trials are undertaken.
In summary, severe ICP in the UK affects 0.1% of
pregnant women and is associated with an increased
risk of preterm delivery, neonatal unit admission, and
stillbirth. The risk of these perinatal complications
increases with increasing levels of maternal serum bile
acids. These findings support the current practice of
close antenatal monitoring and indicate the need for a
randomized controlled trial to assess the benefit of
treatment at reducing these risks.
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